331 related articles for article (PubMed ID: 35217809)
1. FXR: structures, biology, and drug development for NASH and fibrosis diseases.
Tian SY; Chen SM; Pan CX; Li Y
Acta Pharmacol Sin; 2022 May; 43(5):1120-1132. PubMed ID: 35217809
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
3. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.
Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D
Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893
[TBL] [Abstract][Full Text] [Related]
4. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
Zhou W; Anakk S
Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
[TBL] [Abstract][Full Text] [Related]
5. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
[TBL] [Abstract][Full Text] [Related]
6. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor modulators 2014-present: a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
[TBL] [Abstract][Full Text] [Related]
10. FXR modulators for enterohepatic and metabolic diseases.
Wang H; He Q; Wang G; Xu X; Hao H
Expert Opin Ther Pat; 2018 Nov; 28(11):765-782. PubMed ID: 30259754
[TBL] [Abstract][Full Text] [Related]
11. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
Wang K; Zhang Y; Wang G; Hao H; Wang H
Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
[TBL] [Abstract][Full Text] [Related]
12. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists.
Shen T; Shi A; Wei Y; Luo X; Xi L
Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997
[TBL] [Abstract][Full Text] [Related]
15. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
16. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of farnesoid X receptor agonists.
Ali AH; Carey EJ; Lindor KD
Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor modulators (2011 - 2014): a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
